Blue-Chip Pharma Major Records 6-Year High, Top Gainer on Nifty Pharma

By Malvika Gurung

Investing.com — The country’s largest pharmaceutical company, Sun Pharma (NS:) ended up 1.18% at Rs 893.95 apiece, after rising 2% to Rs 900.95 apiece on Friday, recording thus a more than six-year high on the BSE.

The surge in equities was extended by its strong operational performance during the last quarter of December 2021, as it recorded an 11% year-on-year increase in its consolidated revenue to Rs 9,814.2 crore in the third quarter of the year. 22, driven by robust growth in key markets, India and the United States. .

Over the past 8 sessions, the drugmaker has zoomed 13%, and like trading, today at its highest level since October 2015, a newsfeed said.

On the index, only 3 out of 20 stocks finished in the green, led by Sun Pharma, while on the index, the stock was among the top 3 gainers on Friday.

Holding an 8.2% share in the Indian market worth Rs 1.67 trillion, Sun Pharma’s net profit increased by more than 11% year-on-year to Rs 2,058.8 crore, while its EBITDA stood at Rs 2,557.4 crore in the third quarter of FY22.

However, the pharmaceutical heavyweight’s Ebitda margin slipped 80 basis points year-on-year to 26.4% in the quarter under review, driven by a slight decline in gross margins and an increase in expenses.

Additionally, the company’s board of directors announced an interim dividend of Rs 7/share.

Sun Pharma’s business growth in India has exceeded market growth, leading to an increase in market share. Despite rising costs, its profitability is growing.

For more news and quick updates, follow us on our Twitter channel (NYSE:): https://bit.ly/3G7wrVp and Facebook page (NASDAQ:): https://bit.ly/3H2xK9g

Comments are closed.